MedPath

TAVABOROLE

These highlights do not include all the information needed to use TAVABOROLE TOPICAL SOLUTION safely and effectively. See full prescribing information for TAVABOROLE TOPICAL SOLUTION. TAVABOROLE topical solutionInitial U.S. Approval: 2014

Approved
Approval ID

37004451-0345-4e00-96be-f05db600fb9f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 9, 2024

Manufacturers
FDA

Cipla USA Inc.

DUNS: 078719707

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TAVABOROLE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69097-686
Application NumberANDA212224
Product Classification
M
Marketing Category
C73584
G
Generic Name
TAVABOROLE
Product Specifications
Route of AdministrationTOPICAL
Effective DateJanuary 9, 2024
FDA Product Classification

INGREDIENTS (4)

TAVABOROLEActive
Quantity: 43.5 mg in 1 mL
Code: K124A4EUQ3
Classification: ACTIB
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TAVABOROLE - FDA Drug Approval Details